|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT01397695 |
|
Date of registration:
|
18/07/2011 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
|
|
Scientific title:
|
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
|
Date of first enrolment:
|
June 2009 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT01397695 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Terence Davidson, M.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
UCSD |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Adults over the age of 18
- Both male and non-pregnant females adults capable of making informed consent who have
HHT by Curacao criteria and whose nasal bleeding due to HHT is of such a magnitude
that it requires medical care
- Additionally, females of childbearing age will be given a pregnancy test as a
preliminary measure to ensure that those who become involved are not at risk.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Hereditary Hemorrhagic Telangiectasia (HHT)
|
|
Intervention(s)
|
|
Drug: Bevacizumab
|
|
Primary Outcome(s)
|
|
Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.
[Time Frame: 1-2 years]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|